Asia-Pacific: Medicaments Containing Insulin Market 2023

Medicaments Containing Insulin Market Size in Asia-Pacific

The Asia-Pacific medicaments containing insulin market expanded markedly to $X in 2021, surging by 12% against the previous year. Over the period under review, consumption, however, saw a abrupt curtailment. Over the period under review, the market hit record highs at $X in 2012; however, from 2013 to 2021, consumption failed to regain momentum.

Medicaments Containing Insulin Production in Asia-Pacific

In value terms, medicaments containing insulin production stood at $X in 2021 estimated in export price. Overall, production, however, showed a pronounced reduction. The pace of growth appeared the most rapid in 2013 when the production volume increased by 10%. As a result, production reached the peak level of $X. From 2014 to 2021, production growth remained at a somewhat lower figure.

Medicaments Containing Insulin Exports

Exports in Asia-Pacific

In 2021, overseas shipments of medicaments containing insulin but not antibiotics decreased by -34.4% to X tons for the first time since 2017, thus ending a three-year rising trend. Over the period under review, exports saw a deep slump. The pace of growth was the most pronounced in 2020 with an increase of 102%. Over the period under review, the exports hit record highs at X tons in 2013; however, from 2014 to 2021, the exports remained at a lower figure.

In value terms, medicaments containing insulin exports dropped to $X in 2021. In general, exports showed a significant curtailment. The growth pace was the most rapid in 2020 when exports increased by 50%. The level of export peaked at $X in 2013; however, from 2014 to 2021, the exports stood at a somewhat lower figure.

Exports by Country

Thailand prevails in exports structure, resulting at X tons, which was near 86% of total exports in 2021. Australia (X tons) held the second position in the ranking, followed by India (X tons). All these countries together took approx. 10% share of total exports. Hong Kong SAR (X tons) followed a long way behind the leaders.

Thailand was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics exports, with a CAGR of +102.4% from 2012 to 2021. At the same time, Hong Kong SAR (+70.1%) and Australia (+42.5%) displayed positive paces of growth. By contrast, India (-35.1%) illustrated a downward trend over the same period. From 2012 to 2021, the share of Thailand, Australia and Hong Kong SAR increased by +86, +5.1 and +2.9 percentage points, respectively.

In value terms, Thailand ($X), Australia ($X) and Hong Kong SAR ($X) constituted the countries with the highest levels of exports in 2021, with a combined 93% share of total exports.

Among the main exporting countries, Hong Kong SAR, with a CAGR of +99.7%, recorded the highest growth rate of the value of exports, over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

In 2021, the export price in Asia-Pacific amounted to $X per ton, increasing by 36% against the previous year. In general, the export price, however, continues to indicate a deep downturn. The level of export peaked at $X per ton in 2012; however, from 2013 to 2021, the export prices stood at a somewhat lower figure.

There were significant differences in the average prices amongst the major exporting countries. In 2021, amid the top suppliers, the country with the highest price was Australia ($X per ton), while India ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Hong Kong SAR (+17.4%), while the other leaders experienced a decline in the export price figures.

Medicaments Containing Insulin Imports

Imports in Asia-Pacific

In 2021, supplies from abroad of medicaments containing insulin but not antibiotics was finally on the rise to reach X tons after three years of decline. Over the period under review, imports, however, recorded a abrupt descent. The most prominent rate of growth was recorded in 2017 when imports increased by 178%. The volume of import peaked at X tons in 2012; however, from 2013 to 2021, imports failed to regain momentum.

In value terms, medicaments containing insulin imports surged to $X in 2021. In general, imports, however, showed a precipitous descent. The pace of growth appeared the most rapid in 2020 when imports increased by 50% against the previous year. The level of import peaked at $X in 2012; however, from 2013 to 2021, imports failed to regain momentum.

Imports by Country

Malaysia was the largest importing country with an import of about X tons, which amounted to 59% of total imports. It was distantly followed by Japan (X tons), creating a 20% share of total imports. India (X tons), Pakistan (X tons), Sri Lanka (X tons), Myanmar (X tons) and New Caledonia (X tons) followed a long way behind the leaders.

Imports into Malaysia increased at an average annual rate of +2.0% from 2012 to 2021. At the same time, Japan (+32.4%), Sri Lanka (+7.1%) and New Caledonia (+6.9%) displayed positive paces of growth. Moreover, Japan emerged as the fastest-growing importer imported in Asia-Pacific, with a CAGR of +32.4% from 2012-2021. India, Myanmar and Pakistan experienced a relatively flat trend pattern. Malaysia (+49 p.p.), Japan (+20 p.p.), India (+2.6 p.p.), Pakistan (+2.1 p.p.) and Sri Lanka (+1.9 p.p.) significantly strengthened its position in terms of the total imports, while the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, Japan ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in Asia-Pacific, comprising 47% of total imports. The second position in the ranking was taken by Malaysia ($X), with a 14% share of total imports. It was followed by India, with an 8.9% share.

From 2012 to 2021, the average annual rate of growth in terms of value in Japan totaled +61.7%. The remaining importing countries recorded the following average annual rates of imports growth: Malaysia (+4.2% per year) and India (-1.2% per year).

Import Prices by Country

In 2021, the import price in Asia-Pacific amounted to $X per ton, surging by 33% against the previous year. In general, the import price, however, continues to indicate a abrupt decrease. The most prominent rate of growth was recorded in 2020 an increase of 65%. Over the period under review, import prices hit record highs at $X per ton in 2014; however, from 2015 to 2021, import prices failed to regain momentum.

There were significant differences in the average prices amongst the major importing countries. In 2021, amid the top importers, the country with the highest price was New Caledonia ($X per ton), while Malaysia ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Japan (+22.1%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Market Intelligence Platform

Frequently Asked Questions (FAQ) :